Karthik Chintharala

Dr. Karthik Chintharala


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2025 in Brain and Behavior
Verified
Journal Article
Open access
RRRameesha Rauf
Rameesha Rauf
SASalwa Asif
Salwa Asif
AAAbdallah AlSaafeen
Abdallah AlSaafeen
KDKaviprada Geathaa Dhantapaani
Kaviprada Geathaa Dhantapaani
MNMaryam Muhammad Nadeem
Maryam Muhammad Nadeem
ACAsad Ali Ahmed Cheema
Asad Ali Ahmed Cheema
Introduction: Narcolepsy Type 1 (NT1) is a chronic neurological disorder characterized by excessive daytime sleepiness (EDS), cataplexy, and REM intrusions, caused by a deficiency of orexin (hypocretin), a hypothalamic neuropeptide essential for arousal, REM sleep regulation, metabolism, and emotional stability. This review synthesizes and critically analyzes the pathophysiological, clinical, and therapeutic dimensions of orexin deficiency in narcolepsy, with particular emphasis on recent advances from 2023 to 2025. Methods: This narrative analytical review analyzed 50 peer‐reviewed publications covering the neurobiology of the orexin system, diagnostic evolution of NT1, comparative symptomatology of central hypersomnia disorders, and recent therapeutic innovations. Out of which 16 studies were selected based on relevance, recency, and translational impact. Results: Recent research confirms that over 90% of NT1 patients exhibit cerebrospinal fluid (CSF) orexin‐A levels below 110 pg/mL and carry the HLA‐DQB1*06:02 allele, indicating a strong genetic and immunological association. Postmortem analyses have revealed a loss of up to 95% of orexin‐producing neurons in the lateral hypothalamus. In a 2024 multicenter trial, danavorexton (a selective orexin receptor‐2 [OX2R] agonist) was associated with a mean improvement of 11.1 points on the Maintenance of Wakefulness Test, outperforming modafinil and suggesting the feasibility of receptor‐level restoration. In addition, intermediate orexin levels (110–200 pg/mL) have been documented in a subset of patients with narcolepsy Type 2 (NT2) and idiopathic hypersomnia (IH), challenging the binary diagnostic threshold and prompting reevaluation of orexin's diagnostic role. Orexin dysfunction has also been correlated with high psychiatric comorbidity rates, including major depressive disorder in 40% and anxiety disorders in nearly 30% of NT1 patients. These manifestations reflect orexin's broader role in regulating REM sleep, metabolic processes, and autonomic stability. Conclusion: Orexin deficiency remains the central mechanism underlying NT1, with far‐reaching implications in psychiatric and neurodegenerative disease. While emerging orexin‐targeted therapies offer promising disease‐modifying potential, critical challenges persist in standardizing biomarkers, resolving NT2 classification ambiguities, and ensuring global access to therapeutics.

15 February 2025 in Inflammopharmacology
Verified
Journal Article
Closed access
MPMable Pereira
Mable Pereira
AFAncy Jenil Franco
Ancy Jenil Franco
KCKarthik Chintharala
Karthik Chintharala
AVAna Carolina Putini Vieira
Ana Carolina Putini Vieira
AJAna Carolina Ventura de Santana de Jesus
Ana Carolina Ventura de Santana de Jesus
KRKristian Reich
Kristian Reich

28 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Jamir Pitton RissardoJamir Pitton Rissardo
Jamir Pitton Rissardo
ATAmritaa Thalla
Amritaa Thalla
KCKarthik Chintharala
Karthik Chintharala
ACAna Leticia Fornari Caprara
Ana Leticia Fornari Caprara
Background: Excessive daytime sleepiness (EDS) and fatigue are prevalent non-motor symptoms of Parkinson’s disease (PD). Modafinil has been proposed as a management strategy. Evidence across individual trials remains inconsistent. This study aimed to evaluate the efficacy and safety of modafinil compared to placebo on motor and non-motor outcomes in PD. Methods: A systematic search of PubMed/Medline, Embase, and Cochrane Library databases was conducted for trials evaluating modafinil in PD up to March 2026. Inverse-variance methods with fixed-effect or random-effects models were used to determine weighted mean differences (MD) or standardized mean differences (SMD). The statistical heterogeneity was assessed using the I² statistic. Risk of bias was assessed using the Cochrane RoB 2 tool. PROSPERO (CRD420261420008). Results: Seven trials (N = 216; modafinil n = 113, placebo n = 103) met predefined eligibility criteria. Modafinil was associated with a significant reduction in EDS as measured by the Epworth Sleepiness Scale compared to placebo (MD −2.12; 95% CI −3.64 to −0.60; I2 = 65%). No significant effects were observed for fatigue (MD −0.17; 95% CI −1.12 to 0.79), depressive symptoms (SMD 1.51; 95% CI −0.10 to 3.11), or motor function (SMD 0.20; 95% CI −0.23 to 0.63). Adverse events, including insomnia, headache, dizziness, and gastrointestinal symptoms, were comparable between treatment and placebo groups. Conclusion: Modafinil may provide a modest but statistically significant improvement in EDS in PD without worsening motor function or increasing adverse events. No benefit could be elicited for fatigue or depressive symptoms. Larger, longer-duration trials with standardized outcome measures are warranted.

11 November 2026 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
SCSrijita Chatterjee
Srijita Chatterjee
KTKhalid Taha
Khalid Taha
HUHelena Beckhäuser Ubaldo
Helena Beckhäuser Ubaldo
KCKarthik Chintharala
Karthik Chintharala
JSJoao Roberto De Sa
Joao Roberto De Sa